These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 26249023)

  • 1. DBC1/CCAR2 is involved in the stabilization of androgen receptor and the progression of osteosarcoma.
    Wagle S; Park SH; Kim KM; Moon YJ; Bae JS; Kwon KS; Park HS; Lee H; Moon WS; Kim JR; Jang KY
    Sci Rep; 2015 Aug; 5():13144. PubMed ID: 26249023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acetylation status of P53 and the expression of DBC1, SIRT1, and androgen receptor are associated with survival in clear cell renal cell carcinoma patients.
    Noh SJ; Kang MJ; Kim KM; Bae JS; Park HS; Moon WS; Chung MJ; Lee H; Lee DG; Jang KY
    Pathology; 2013 Oct; 45(6):574-80. PubMed ID: 24018803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma.
    Cho D; Park H; Park SH; Kim K; Chung M; Moon W; Kang M; Jang K
    J Ovarian Res; 2015 Feb; 8():2. PubMed ID: 25823848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CK2α phosphorylates DBC1 and is involved in the progression of gastric carcinoma and predicts poor survival of gastric carcinoma patients.
    Bae JS; Park SH; Kim KM; Kwon KS; Kim CY; Lee HK; Park BH; Park HS; Lee H; Moon WS; Chung MJ; Sylvester KG; Jang KY
    Int J Cancer; 2015 Feb; 136(4):797-809. PubMed ID: 24962073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FAM83H is involved in stabilization of β-catenin and progression of osteosarcomas.
    Kim KM; Hussein UK; Park SH; Kang MA; Moon YJ; Zhang Z; Song Y; Park HS; Bae JS; Park BH; Ha SH; Moon WS; Kim JR; Jang KY
    J Exp Clin Cancer Res; 2019 Jun; 38(1):267. PubMed ID: 31215499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The overexpression of DBC1 in esophageal squamous cell carcinoma correlates with poor prognosis.
    Kim SH; Kim JH; Yu EJ; Lee KW; Park CK
    Histol Histopathol; 2012 Jan; 27(1):49-58. PubMed ID: 22127596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High DBC1 (CCAR2) expression in gallbladder carcinoma is associated with favorable clinicopathological factors.
    Won KY; Cho H; Kim GY; Lim SJ; Bae GE; Lim JU; Sung JY; Park YK; Kim YW; Lee J
    Int J Clin Exp Pathol; 2015; 8(9):11440-5. PubMed ID: 26617872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deleted in breast cancer 1, a novel androgen receptor (AR) coactivator that promotes AR DNA-binding activity.
    Fu J; Jiang J; Li J; Wang S; Shi G; Feng Q; White E; Qin J; Wong J
    J Biol Chem; 2009 Mar; 284(11):6832-40. PubMed ID: 19126541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of DBC1, correlated with poor prognosis, is a potential therapeutic target for hepatocellular carcinoma.
    Li C; Liao J; Wu S; Fan J; Peng Z; Wang Z
    Biochem Biophys Res Commun; 2017 Dec; 494(3-4):511-517. PubMed ID: 29106957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. XB130 expression in human osteosarcoma: a clinical and experimental study.
    Wang X; Wang R; Liu Z; Hao F; Huang H; Guo W
    Int J Clin Exp Pathol; 2015; 8(3):2565-73. PubMed ID: 26045762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of DBC1 and Androgen Receptor Predict Poor Prognosis in Diffuse Large B Cell Lymphoma.
    Park HS; Bae JS; Noh SJ; Kim KM; Lee H; Moon WS; Chung MJ; Kang MJ; Lee DG; Jang KY
    Transl Oncol; 2013 Jun; 6(3):370-81. PubMed ID: 23730418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma.
    Cha EJ; Noh SJ; Kwon KS; Kim CY; Park BH; Park HS; Lee H; Chung MJ; Kang MJ; Lee DG; Moon WS; Jang KY
    Clin Cancer Res; 2009 Jul; 15(13):4453-9. PubMed ID: 19509139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia-induced proteasomal degradation of DBC1 by SIAH2 in breast cancer progression.
    Liu Q; Luo Q; Feng J; Zhao Y; Ma B; Cheng H; Zhao T; Lei H; Mu C; Chen L; Meng Y; Zhang J; Long Y; Su J; Chen G; Li Y; Hu G; Liao X; Chen Q; Zhu Y
    Elife; 2022 Aug; 11():. PubMed ID: 35913115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ubiquitin-like protein FAT10 promotes osteosarcoma growth by modifying the ubiquitination and degradation of YAP1.
    Yi X; Deng X; Zhao Y; Deng B; Deng J; Fan H; Du Y; Hao L
    Exp Cell Res; 2020 Feb; 387(2):111804. PubMed ID: 31877302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma.
    Lee H; Kim KR; Noh SJ; Park HS; Kwon KS; Park BH; Jung SH; Youn HJ; Lee BK; Chung MJ; Koh DH; Moon WS; Jang KY
    Hum Pathol; 2011 Feb; 42(2):204-13. PubMed ID: 21056897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11.
    Liao Y; Sassi S; Halvorsen S; Feng Y; Shen J; Gao Y; Cote G; Choy E; Harmon D; Mankin H; Hornicek F; Duan Z
    Sci Rep; 2017 Mar; 7():43941. PubMed ID: 28262798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MALAT1 promotes the proliferation and metastasis of osteosarcoma cells by activating the PI3K/Akt pathway.
    Dong Y; Liang G; Yuan B; Yang C; Gao R; Zhou X
    Tumour Biol; 2015 Mar; 36(3):1477-86. PubMed ID: 25431257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of DBC1 is associated with poor prognosis in hepatitis virus-related hepatocellular carcinoma.
    Ha SY; Kim JH; Yang JW; Bae H; Cho HY; Park CK
    Pathol Res Pract; 2016 Jul; 212(7):616-21. PubMed ID: 27083241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of microRNA-223/epithelial cell transforming sequence 2 signaling in patients with osteosarcoma.
    Zhang H; Yin Z; Ning K; Wang L; Guo R; Ji Z
    Hum Pathol; 2014 Jul; 45(7):1430-6. PubMed ID: 24784921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A positive role of DBC1 in PEA3-mediated progression of estrogen receptor-negative breast cancer.
    Kim HJ; Kim SH; Yu EJ; Seo WY; Kim JH
    Oncogene; 2015 Aug; 34(34):4500-8. PubMed ID: 25417701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.